| Chromothripsis in acute myeloid leukemia: biological features and impact on survival MC Fontana, G Marconi, JDM Feenstra, E Fonzi, C Papayannidis, ... Leukemia 32 (7), 1609-1620, 2018 | 105 | 2018 |
| Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia … G Corradi, C Baldazzi, D Očadlíková, G Marconi, S Parisi, N Testoni, ... Stem cell research & therapy 9, 1-15, 2018 | 85 | 2018 |
| First report of the Gimema LAL1811 phase II prospective study of the combination of steroids with ponatinib as frontline therapy of elderly or unfit patients with Philadelphia … G Martinelli, A Piciocchi, C Papayannidis, S Paolini, V Robustelli, ... Blood 130, 99, 2017 | 76 | 2017 |
| Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery G Simonetti, A Padella, IF do Valle, MC Fontana, E Fonzi, S Bruno, ... Cancer 125 (5), 712-725, 2019 | 57 | 2019 |
| INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia G Martinelli, C Papayannidis, A Piciocchi, V Robustelli, S Soverini, ... Blood advances 6 (6), 1742-1753, 2022 | 49 | 2022 |
| Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia A Ghelli Luserna Di Rorà, N Beeharry, E Imbrogno, A Ferrari, V Robustelli, ... Journal of hematology & oncology 11, 1-18, 2018 | 39 | 2018 |
| Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies A Padella, A Ghelli Luserna Di Rorà, G Marconi, M Ghetti, G Martinelli, ... Journal of hematology & oncology 15 (1), 10, 2022 | 38 | 2022 |
| Genome-wide association study identifies susceptibility loci for acute myeloid leukemia WY Lin, SE Fordham, E Hungate, NJ Sunter, C Elstob, Y Xu, C Park, ... Nature Communications 12 (1), 6233, 2021 | 24 | 2021 |
| Acute myeloid leukemia mutations: therapeutic implications C Papayannidis, C Sartor, G Marconi, MC Fontana, J Nanni, G Cristiano, ... International Journal of Molecular Sciences 20 (11), 2721, 2019 | 23 | 2019 |
| Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients E Zuffa, E Franchini, C Papayannidis, C Baldazzi, G Simonetti, N Testoni, ... Oncotarget 6 (31), 31284, 2015 | 23 | 2015 |
| Synergism through WEE1 and CHK1 inhibition in acute lymphoblastic leukemia A Ghelli Luserna Di Rorà, M Bocconcelli, A Ferrari, C Terragna, S Bruno, ... Cancers 11 (11), 1654, 2019 | 22 | 2019 |
| Broad activity for the pivekimab sunirine (PVEK, IMGN632), azacitidine, and venetoclax triplet in high-risk patients with relapsed/refractory acute myeloid leukemia (AML) N Daver, P Montesinos, A Aribi, G Marconi, JK Altman, ES Wang, ... Blood 140 (Supplement 1), 145-149, 2022 | 21 | 2022 |
| Safety of FLT3 inhibitors in patients with acute myeloid leukemia C Cerchione, A Peleteiro Raindo, A Mosquera Orgueira, ... Expert Review of Hematology 14 (9), 851-865, 2021 | 20 | 2021 |
| Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations G Simonetti, C Mengucci, A Padella, E Fonzi, G Picone, C Delpino, ... Leukemia 35 (10), 2813-2826, 2021 | 19 | 2021 |
| Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia L Bertamini, J Nanni, G Marconi, M Abbenante, V Robustelli, F Bacci, ... BMC cancer 18, 1-5, 2018 | 18 | 2018 |
| AVALON: The Italian cohort study on real‐life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia E Todisco, C Papayannidis, N Fracchiolla, E Petracci, C Zingaretti, ... Cancer 129 (7), 992-1004, 2023 | 17 | 2023 |
| An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia S Ragaini, S Wagner, G Marconi, S Parisi, C Sartor, J Nanni, G Cristiano, ... Blood Advances 6 (1), 87-99, 2022 | 15 | 2022 |
| Hypomethylating agent-based combination therapies to treat post-hematopoietic stem cell transplant relapse of acute myeloid leukemia G Ciotti, G Marconi, G Martinelli Frontiers in Oncology 11, 810387, 2022 | 10 | 2022 |
| Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant C Papayannidis, C Sartor, A Dominietto, E Zappone, M Arpinati, ... Hematological Oncology 39 (4), 580-583, 2021 | 9 | 2021 |
| Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating … C Papayannidis, J Nanni, G Cristiano, G Marconi, C Sartor, S Parisi, ... European Journal of Haematology 108 (6), 449-459, 2022 | 7 | 2022 |
